Assembly Biosciences Inc (ASMB)

Currency in USD
21.120
+0.940(+4.66%)
Closed·
21.280+0.160(+0.76%)
·
ASMB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
19.22021.210
52 wk Range
19.20039.705
Key Statistics
Prev. Close
21.12
Open
19.96
Day's Range
19.22-21.21
52 wk Range
19.2-39.705
Volume
318.87K
Average Volume (3m)
307.91K
1-Year Change
-42.468%
Book Value / Share
14.68
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ASMB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
51.200
Upside
+142.42%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Assembly Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 51.200
(+142.42% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy48.00+127.27%52.00MaintainNov 03, 2026
UBS
Buy52.00+146.21%-New CoverageSep 01, 2026
Mizuho
Buy45.00+113.07%53.00MaintainAug 31, 2026
H.C. Wainwright
Buy50.00+136.74%-MaintainAug 18, 2026
Mizuho
Buy45.00+113.07%40.00MaintainJun 15, 2026

Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
-0.93 / -0.62
Revenue / Forecast
2.96M / 7.93M
EPS Revisions
Last 90 days

ASMB Income Statement

Compare ASMB to Peers and Sector

Metrics to compare
ASMB
Peers
Sector
Relationship
P/E Ratio
−39.0x−1.5x−0.2x
PEG Ratio
−0.44−0.040.00
Price/Book
1.4x2.1x2.6x
Price / LTM Sales
6.5x5.7x2.8x
Upside (Analyst Target)
142.4%133.0%65.0%
Fair Value Upside
Unlock21.9%9.6%Unlock

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.55M12.54%57.13M
Other Institutional Investors
19.90M87.46%445.26M
Public Companies & Retail Investors
0.000.00%0.00
Total
22.46M100.00%502.39M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Gilead Sciences, Inc.24.44%4,977,089111,337
Farallon Capital Management, L.L.C.7.88%1,604,59035,895

People Also Watch

13.90
OGN
0.00%
409.10
APP
+3.92%
519.43
AMP
+1.16%
165.04
ALNY
+5.36%
450.00
HUM
+1.42%

FAQ

What Is the Assembly Biosciences (ASMB) Stock Price Today?

The Assembly Biosciences stock price today is 21.120 USD.

What Stock Exchange Does Assembly Biosciences Trade On?

Assembly Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Assembly Biosciences?

The stock symbol for Assembly Biosciences is "ASMB."

What Is the Assembly Biosciences Market Cap?

As of today, Assembly Biosciences market cap is 413.230M USD.

What Is Assembly Biosciences's Earnings Per Share (TTM)?

The Assembly Biosciences EPS (TTM) is -0.60.

When Is the Next Assembly Biosciences Earnings Date?

Assembly Biosciences will release its next earnings report on Mar 25, 2027.

From a Technical Analysis Perspective, Is ASMB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Assembly Biosciences Stock Split?

Assembly Biosciences has split 2 times.

How Many Employees Does Assembly Biosciences Have?

Assembly Biosciences has 73 employees.

What is the current trading status of Assembly Biosciences (ASMB)?

As of Nov 14, 2026, Assembly Biosciences (ASMB) is trading at a price of 21.120 USD, with a previous close of 21.120 USD. The stock has fluctuated within a day range of 19.220 USD to 21.210 USD, while its 52-week range spans from 19.200 USD to 39.705 USD.

What Is Assembly Biosciences (ASMB) Price Target According to Analysts?

The average 12-month price target for Assembly Biosciences is 51.200 USD, with a high estimate of 62 USD and a low estimate of 43 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +142.42% Upside potential.

What Is the ASMB Premarket Price?

ASMB's last pre-market stock price is 20.060 USD. The pre-market share volume is 230.000, and the stock has decreased by -0.120, or -0.590%.

What Is the ASMB After Hours Price?

ASMB's last after hours stock price is 21.280 USD, the stock has decreased by 0.160, or 0.760%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.